Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
First Investment: 2018
Understanding the changing shapes of cells as they grow is one key to understanding the biology of development and disease, but it’s hard to quantify morphology by eye. Deepcell’s benchtop microfluidics technology dissociates, sorts, and images single cells. Then the company’s machine learning software identifies distinguishing morphology, all without labeling or training. The resulting data opens the door for breakthroughs in cancer research, cell therapy, and developmental biology.
Explore Companies
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules